Commonwealth Equity Services’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-10,934
| Closed | -$236K | – | 4313 |
|
|
2025
Q4 | $236K | Sell |
10,934
-4,661
| -30% | -$90.5K | ﹤0.01% | 3845 |
|
|
2025
Q3 | $238K | Sell |
15,595
-1,484
| -9% | -$19.3K | ﹤0.01% | 3822 |
|
|
2025
Q2 | $151K | Sell |
17,079
-1,685
| -9% | -$14.8K | ﹤0.01% | 3989 |
|
|
2025
Q1 | $147K | Sell |
18,764
-18,960
| -50% | -$159K | ﹤0.01% | 3921 |
|
|
2024
Q4 | $396K | Sell |
37,724
-6,264
| -14% | -$76.1K | ﹤0.01% | 3162 |
|
|
2024
Q3 | $577K | Sell |
43,988
-779
| -2% | -$11.9K | ﹤0.01% | 2771 |
|
|
2024
Q2 | $629K | Buy |
44,767
+5,460
| +14% | +$89K | ﹤0.01% | 2639 |
|
|
2024
Q1 | $664K | Sell |
39,307
-40,875
| -51% | -$609K | ﹤0.01% | 2575 |
|
|
2023
Q4 | $1.13M | Buy |
80,182
+969
| +1% | +$11.4K | ﹤0.01% | 2093 |
|
|
2023
Q3 | $816K | Buy |
79,213
+2,528
| +3% | +$33.9K | ﹤0.01% | 2217 |
|
|
2023
Q2 | $1.26M | Buy |
76,685
+32,150
| +72% | +$418K | ﹤0.01% | 1931 |
|
|
2023
Q1 | $407K | Buy |
44,535
+3,904
| +10% | +$32.1K | ﹤0.01% | 2723 |
|
|
2022
Q4 | $290K | Buy |
40,631
+7,942
| +24% | +$55.7K | ﹤0.01% | 2888 |
|
|
2022
Q3 | $163K | Buy |
32,689
+17,000
| +108% | +$93.6K | ﹤0.01% | 3253 |
|
|
2022
Q2 | $38K | Sell |
15,689
-447
| -3% | -$1.83K | ﹤0.01% | 3519 |
|
|
2022
Q1 | $110K | Buy |
16,136
+1,000
| +7% | +$6.87K | ﹤0.01% | 3461 |
|
|
2021
Q4 | $122K | Sell |
15,136
-1,621
| -10% | -$14.8K | ﹤0.01% | 3418 |
|
|
2021
Q3 | $164K | Sell |
16,757
-2,120
| -11% | -$16.7K | ﹤0.01% | 3331 |
|
|
2021
Q2 | $127K | Sell |
18,877
-1,700
| -8% | -$13.5K | ﹤0.01% | 3368 |
|
|
2021
Q1 | $186K | Buy |
20,577
+6,650
| +48% | +$53.8K | ﹤0.01% | 3151 |
|
|
2020
Q4 | $93K | Sell |
13,927
-850
| -6% | -$5.32K | ﹤0.01% | 3073 |
|
|
2020
Q3 | $74K | Buy |
14,777
+535
| +4% | +$3.89K | ﹤0.01% | 2915 |
|
|
2020
Q2 | $115K | Buy |
+14,242
| New | +$126K | ﹤0.01% | 2748 |
|
Other funds holding AVDL
Commonwealth Equity Services's AVDL Position: Q1 2026 in Review
Commonwealth Equity Services sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 10,934 shares — an estimated $236K sold.
Commonwealth Equity Services first reported a position in AVDL in Q2 2020 and held it in 23 quarters. The position peaked at $1.26M in Q2 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Commonwealth Equity Services reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Commonwealth Equity Services sold 10,934 Avadel Pharmaceuticals shares in Q1 2026, an estimated $236K.
- Commonwealth Equity Services first reported a position in Avadel Pharmaceuticals in Q2 2020 and held it in 23 quarters.
- Commonwealth Equity Services's Avadel Pharmaceuticals position peaked at $1.26M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.